Over the past 12 months, 0 insiders at Intra-Cellular Therapies, Inc. filed 0 open-market SEC Form 4 transactions on ITCI: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 5, 24 | Sharon MatesChairman and CEO | SELL | 50.2K | $84.69 | $4.2M |
| Dec 4, 24 | Sharon MatesChairman and CEO | SELL | 27.7K | $86.00 | $2.4M |
| Nov 13, 24 | Michael HalsteadPresident | SELL | 13.4K | $88.92 | $1.2M |
| Nov 12, 24 | Michael HalsteadPresident | SELL | 15.1K | $90.89 | $1.3M |
| Aug 30, 24 | Sharon MatesChairman and CEO | SELL | 28.2K | $73.32 | $2.1M |
| Aug 29, 24 | Sharon MatesChairman and CEO | SELL | 29.8K | $73.25 | $2.2M |
| Aug 28, 24 | Sharon MatesChairman and CEO | SELL | 32.5K | $73.70 | $2.4M |
| Aug 27, 24 | Sharon MatesChairman and CEO | SELL | 23.7K | $73.93 | $1.7M |
| Aug 26, 24 | Sharon MatesChairman and CEO | SELL | 22.7K | $74.59 | $1.7M |
| Aug 23, 24 | Sharon MatesChairman and CEO | SELL | 28.7K | $74.46 | $2.1M |
| Aug 22, 24 | Sharon MatesChairman and CEO | SELL | 35.0K | $75.47 | $2.6M |
| Aug 21, 24 | Sharon MatesChairman and CEO | SELL | 44.1K | $77.98 | $3.3M |
| Aug 16, 24 | Mark NeumannEVP, Chief Commercial Officer | SELL | 18.7K | $75.08 | $1.4M |
| Jun 24, 24 | Rory B RiggsDirector | SELL | 4.5K | $75.57 | $337K |
| Jun 18, 24 | Van Nostrand Robert LDirector | SELL | 11.1K | $76.07 | $845K |
| Mar 11, 24 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 2.2K | $66.96 | $142K |
| Mar 11, 24 | Michael HalsteadEVP and General Counsel | SELL | 6.1K | $66.70 | $402K |
| Mar 11, 24 | Lawrence J. HinelineSVP of Finance, CFO | SELL | 4.5K | $67.32 | $297K |
| Mar 11, 24 | Sharon MatesChairman, President & CEO | SELL | 14.5K | $67.33 | $942K |
| Mar 11, 24 | Mark NeumannEVP, Chief Commercial Officer | SELL | 4.3K | $66.86 | $280K |
| Mar 7, 24 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 3.7K | $66.86 | $247K |
| Mar 7, 24 | Michael HalsteadEVP and General Counsel | SELL | 12.9K | $66.81 | $854K |
| Mar 7, 24 | Lawrence J. HinelineSVP of Finance, CFO | SELL | 6.6K | $66.93 | $443K |
| Mar 7, 24 | Sharon MatesChairman, President & CEO | SELL | 32.0K | $66.93 | $2.1M |
| Mar 7, 24 | Mark NeumannEVP, Chief Commercial Officer | SELL | 8.6K | $66.95 | $573K |
| Feb 27, 24 | Van Nostrand Robert LDirector | SELL | 10.3K | $73.14 | $757K |
| Feb 26, 24 | Joel S MarcusDirector | SELL | 17.7K | $69.60 | $1.2M |
| Feb 26, 24 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 1.4K | $71.02 | $98K |
| Feb 26, 24 | Michael HalsteadEVP and General Counsel | SELL | 7.2K | $70.13 | $502K |
| Feb 26, 24 | Lawrence J. HinelineSVP of Finance, CFO | SELL | 6.9K | $70.15 | $476K |
| Feb 26, 24 | Sharon MatesChairman, President & CEO | SELL | 12.5K | $70.11 | $874K |
| Feb 26, 24 | Mark NeumannEVP, Chief Commercial Officer | SELL | 4.1K | $71.18 | $282K |
| Feb 2, 24 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 3.8K | $67.49 | $260K |
| Feb 2, 24 | Michael HalsteadEVP and General Counsel | SELL | 11.1K | $67.17 | $740K |
| Feb 2, 24 | Lawrence J. HinelineSVP of Finance, CFO | SELL | 11.0K | $67.35 | $733K |
| Feb 2, 24 | Sharon MatesChairman, President & CEO | SELL | 17.4K | $67.42 | $1.2M |
| Feb 2, 24 | Mark NeumannEVP, Chief Commercial Officer | SELL | 6.9K | $67.49 | $466K |
| Jan 18, 24 | Sharon MatesChairman, President & CEO | SELL | 67.6K | $66.25 | $4.4M |
| Jan 17, 24 | Sharon MatesChairman, President & CEO | SELL | 30.6K | $66.66 | $2.0M |
| Jan 16, 24 | Sharon MatesChairman, President & CEO | SELL | 66.0K | $67.76 | $4.4M |
| Jan 11, 24 | Michael HalsteadEVP and General Counsel | SELL | 30.4K | $67.80 | $2.0M |
| Jan 2, 24 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 37.4K | $71.77 | $2.6M |
| Dec 13, 23 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 21.3K | $65.00 | $1.4M |
| Nov 13, 23 | Michael HalsteadEVP and General Counsel | SELL | 41.1K | $54.01 | $2.2M |
| Nov 6, 23 | Mark NeumannEVP, Chief Commercial Officer | SELL | 26.8K | $55.98 | $1.5M |
| Sep 19, 23 | Sharon MatesChairman, President & CEO | SELL | 44.4K | $54.17 | $2.4M |
| Sep 18, 23 | Sharon MatesChairman, President & CEO | SELL | 28.1K | $53.96 | $1.5M |
| Aug 7, 23 | Mark NeumannEVP, Chief Commercial Officer | SELL | 55.3K | $58.79 | $3.3M |
| Jul 17, 23 | Suresh K. DurgamEVP, Chief Medical Officer | SELL | 1.8K | $65.00 | $120K |
| Jun 14, 23 | Lawrence J. HinelineSVP of Finance CFO | SELL | 44.0K | $65.01 | $2.8M |
Over the past 12 months, insiders at Intra-Cellular Therapies, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on ITCI, which makes them mixed over the period. The most recent Form 4 was filed on .
0 different insiders at Intra-Cellular Therapies, Inc. filed open-market SEC Form 4 transactions on ITCI over the last 12 months.
InsiderTape plots every ITCI insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Intra-Cellular Therapies, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →